AgeX Therapeutics Ceo Michael D. West To Participate In Roundtable Panel On The Path Forward For Stem Cell Therapy At Termis Americas’ Annual Conference On Tissue Engineering & Regenerative Medicine, December 6 In Charlotte, Nc12/04/2017
ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX) announced today that Chief Executive Officer Michael D. West, Ph.D., is participating on a roundtable panel at Termis Americas’ annual conference & exhibition on Tissue Engineering & Regenerative Medicine, December 6 in Charlotte, North Carolina. Dr. West will describe the AgeX product pipeline, in particular, the emerging field of induced tissue regeneration (iTR). Dr. West’s presentation will be available for viewing at www.agexinc.com.
This year’s conference will focus on the theme, “The Path Forward for Regenerative Medicine: Traversing the Lab to the Patient.” Dr. West will participate in a panel discussion titled “The Coming-of-Age Story of Cell Therapy: Is the Field Mature Enough for Prime Time?” 10:00-11:00 AM EST.
About AgeX Therapeutics
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), is a biotechnology company applying technology relating to cellular immortality and regenerative biology to aging and age-related diseases. The company has three initial areas of product development: pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial planned indications for these products are Type 2 diabetes, cardiac ischemia, and cancer respectively. For more information, please visit www.agexinc.com or connect with the company on Twitter or Facebook.
BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell and drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells, which can become any type of cell in the human body, and cell/drug delivery. Renevia®, a cell delivery product, met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients earlier this year. Submission for approval of Renevia® in the EU is expected to be early 2018, with possible approval and commercial launch in 2018. There were no device related serious adverse events reported. OpRegen®, a retinal pigment epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no related serious adverse events reported. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com.
Investor Contact for BioTime:
David Nakasone, 510-871-4188
Media Contact for AgeX:
Gotham Communications, LLC
Bill Douglass, 646-504-0890